CSPC Pharmaceutical Group's (HKG:1093) investigational new drug application to conduct a clinical trial of SYS6043 has been approved by the U.S. Food and Drug Administration (FDA), a Thursday bourse filing said.
The indication for this approval is advanced/metastatic solid tumors, and the drug is expected to be indicated for the treatment of small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, prostate cancer, and hepatocellular carcinoma.
The pharmaceutical company obtained clinical trial approval from the National Medical Products Administration of China in December 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。